Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Bottorff

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The American Journal of Cardiology|April 4, 2006
Statin safety and drug interactions: clinical implicationsMichael B Bottorff
The American Journal of Geriatric Cardiology|May 11, 2004
Statin safety: what to knowMichael B Bottorff
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Underidentification and undertreatment issuesMichael B Bottorff
Journal of the American Pharmacists Association : Japha|April 21, 2004
New roles for antiplatelet agents in treatment of atherothrombotic diseasesMichael B Bottorff
Journal of Managed Care Pharmacy : JMCP|November 18, 2004
Quality improvement in the continuum of care: impact of atherothrombosis in managed care pharmacyMichael R Toscani, Rajendra Makkar, Michael B Bottorff
Pharmacotherapy|July 28, 2007
Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiativeMichael B Bottorff, Edith A Nutescu, Sarah Spinler
Seminars in Arthritis and Rheumatism|January 29, 2013
Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system databasePranav K Gandhi, William M Gentry, Michael B Bottorff
Advances in Therapy|January 11, 2020
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative ReviewDaniel E Hilleman, Barbara S Wiggins, Michael B Bottorff
Pharmacotherapy|June 28, 2017
Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular DrugsMichael B Bottorff, David R Bright, David F Kisor
Pharmacotherapy|October 4, 2012
Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system databasePranav K Gandhi, William M Gentry, Michael B Bottorff
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The American Journal of Cardiology|April 4, 2006
Statin safety and drug interactions: clinical implicationsMichael B Bottorff
The American Journal of Geriatric Cardiology|May 11, 2004
Statin safety: what to knowMichael B Bottorff
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Underidentification and undertreatment issuesMichael B Bottorff
Journal of the American Pharmacists Association : Japha|April 21, 2004
New roles for antiplatelet agents in treatment of atherothrombotic diseasesMichael B Bottorff
Journal of Managed Care Pharmacy : JMCP|November 18, 2004
Quality improvement in the continuum of care: impact of atherothrombosis in managed care pharmacyMichael R Toscani, Rajendra Makkar, Michael B Bottorff
Pharmacotherapy|July 28, 2007
Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiativeMichael B Bottorff, Edith A Nutescu, Sarah Spinler
Seminars in Arthritis and Rheumatism|January 29, 2013
Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system databasePranav K Gandhi, William M Gentry, Michael B Bottorff
Advances in Therapy|January 11, 2020
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative ReviewDaniel E Hilleman, Barbara S Wiggins, Michael B Bottorff
Pharmacotherapy|June 28, 2017
Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular DrugsMichael B Bottorff, David R Bright, David F Kisor
Pharmacotherapy|October 4, 2012
Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system databasePranav K Gandhi, William M Gentry, Michael B Bottorff
Pageof 2